m+Medelevator.RU
← Поиск публикаций
Science translational medicine · 2017

A role for bacterial urease in gut dysbiosis and Crohn's disease.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ni Josephine, Shen Ting-Chin David, Chen Eric Z, Bittinger Kyle, Bailey Aubrey, Roggiani Manuela, Sirota-Madi Alexandra, Friedman Elliot S, Chau Lillian, Lin Andrew, Nissim Ilana, Scott Justin, Lauder Abigail, Hoffmann Christopher, Rivas Gloriany, Albenberg Lindsey, Baldassano Robert N, Braun Jonathan, Xavier Ramnik J, Clish Clary B, Yudkoff Marc, Li Hongzhe, Goulian Mark, Bushman Frederic D, Lewis James D, Wu Gary D

Аннотация

Gut dysbiosis during inflammatory bowel disease involves alterations in the gut microbiota associated with inflammation of the host gut. We used a combination of shotgun metagenomic sequencing and metabolomics to analyze fecal samples from pediatric patients with Crohn's disease and found an association between disease severity, gut dysbiosis, and bacterial production of free amino acids. Nitrogen flux studies using 15N in mice showed that activity of bacterial urease, an enzyme that releases ammonia by hydrolysis of host urea, led to the transfer of murine host-derived nitrogen to the gut microbiota where it was used for amino acid synthesis. Inoculation of a conventional murine host (pretreated with antibiotics and polyethylene glycol) with commensal Escherichia coli engineered to express urease led to dysbiosis of the gut microbiota, resulting in a predominance of Proteobacteria species. This was associated with a worsening of immune-mediated colitis in these animals. A potential role for altered urease expression and nitrogen flux in the development of gut dysbiosis suggests that bacterial urease may be a potential therapeutic target for inflammatory bowel diseases.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты